| ENLIVEX LTD. IS-,01 |
| Israel |
| Gesundheit |
| IL0011319527 / A119KH |
| 1BT (Frankfurt) / ENLV (NASDAQ) |
| FRA:1BT, ETR:1BT, 1BT:GR, NASDAQ:ENLV |
| - |
| https://www.enlivex.com/ |
|
Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment. Its lead program, Allocetra, is designed to restore immune balance by reprogramming macrophages, with develop..
>Volltext.. |
| 3.08 Mio. EUR |
| 13.53 Mio. EUR |
| - |
| - |
| - |
| - |
| 15.66 Mio. EUR |
| 5.03 Mio. EUR |
| - |
| 0.18 |
| - |
| - |
| - |
| - |
| - |
| - |
| ENLIVEX |
| 28.10.26 |
|
||||
|